Use of HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells as a Potential Therapeutic for Progressive HER2-Positive Glioblastoma.

Use of HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells as a Potential Therapeutic for Progressive HER2-Positive Glioblastoma.

Neurosurgery. 2017 Nov 01;81(5):N42-N43

Authors: Schneider JR, Kwan K, Boockvar JA

PMID: 29088463 [PubMed - in process]

from #PM All via ola Kala on Inoreader http://ift.tt/2zb46yD